Company Overview
The Beauty Health Company operates as a global medical aesthetics entity that delivers an integrated ecosystem of clinically proven solutions across the Americas, Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. By focusing on flagship products like HydraFacial, the firm enhances skin health through a comprehensive approach that spans multiple international regions. The company is categorized within the Consumer Defensive sector, specifically the Household & Personal Products industry, which generally implies a business model that tends to be resilient during economic downturns due to the consistent demand for personal care goods. With a market capitalization of $127.77M, annual revenue of $300.79M, and an employee count of 613, the organization maintains a relatively small-scale footprint compared to larger public peers in the beauty industry. These valuation and revenue figures suggest that the company currently occupies a niche position, likely focusing on specialized medical aesthetics rather than broad consumer mass-market distribution.
Financial Health
The company reported total revenue of $300.79M for the trailing twelve months, while recording a net income of $-9,519,000 and an EBITDA of $4.55M. The significant gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, including the cost of goods sold, administrative costs, and taxes, have exceeded gross profits to the point of generating an overall loss. Despite the net loss, the entity generated free cash flow of $37.97M, which indicates a strong ability to generate liquidity from operations and suggests financial flexibility to fund capital expenditures or repay debt without immediate external financing. The gross margin stands at 65.3%, indicating that the company retains a substantial portion of revenue after accounting for direct production costs, a typical characteristic of branded consumer goods. However, the operating margin is only 0.2%, and the profit margin is -3.2%, highlighting that high fixed costs or inefficient operational leverage are eroding the healthy gross profitability into an operating loss. On the balance sheet, the company holds $230.67M in cash against $378.76M in total debt, resulting in a debt-to-equity ratio of 620.34, which characterizes a highly leveraged financial position reliant on its cash reserves to service obligations. The current ratio of 1.66 indicates that the company possesses sufficient current assets to cover its short-term liabilities, suggesting adequate short-term liquidity despite the long-term debt burden. Furthermore, the return on equity is -16.9% and the return on assets is -2.2%, metrics that reveal that management has not yet generated positive returns on shareholder capital or the asset base, reflecting the current phase of expansion or restructuring that is absorbing profits.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the negative net income, whereas the forward P/E ratio is 7.69, implying that the market expects earnings to recover in the future to justify a valuation based on expected rather than historical profitability. The price-to-book ratio is 2.09, which indicates that the market values the company at a slight premium over its book value, potentially reflecting the intangible value of its brand assets and proprietary medical solutions. Additionally, the price-to-sales ratio is 0.42 and the EV/EBITDA is 60.68, suggesting that the valuation is being assessed on revenue multiples due to earnings volatility, though the high EV/EBITDA multiple points to a potentially expensive valuation relative to current earnings power. The stock has traded between a 52-week high of $2.69 and a 52-week low of $0.78, with the current price trading at a specific point within this range that reflects recent market sentiment on its recovery potential. The beta value is 1.21, meaning the stock price exhibits higher volatility relative to the broader market, moving more aggressively than the average stock during periods of market fluctuation.
Growth & Income
The revenue growth year-over-year is -1.4%, while the earnings growth year-over-year is N/A due to the current lack of positive earnings, indicating that the company is currently in a contraction phase regarding top-line sales rather than experiencing rapid expansion. Since the earnings growth rate is not applicable, there is no positive earnings trajectory to outpace the declining revenue, suggesting that cost reductions or operational improvements are necessary to reverse the negative trends. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the entity retains all available cash flow for reinvestment into business growth rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue momentum and an absence of dividend income, requiring reliance on operational turnaround and future earnings recovery to drive shareholder value.